SLV310, a novel, potential antipsychotic, combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 3, 2003, Pages 405-408

  Van Hes, Rolf ^a   Smid, Pieter ^a   Stroomer, Cees N J ^a   Tipker, Koos ^a   Tulp, Martin Th M ^a   Van Der Heyden, Jan A M ^a   McCreary, Andrew C ^a   Hesselink, Mayke B ^a   Kruse, Chris G ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [4 (5 FLUORO 1H INDOL 3 YL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL]BUTYL]PHTHALIMIDE; 2 [4 [4 (5 FLUORO 1H INDOL 3 YL) 3,6 DIHYDRO 2H PYRIDIN 1 YL] BUTYL]PHTHALIMIDE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHTHALIMIDE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; MOUSE; NONHUMAN; RAT; RECEPTOR BLOCKING; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION;

5-HYDROXYTRYPTOPHAN; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BEHAVIOR, ANIMAL; CHO CELLS; CRICETINAE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDICATORS AND REAGENTS; MICE; MOTOR ACTIVITY; PHTHALIMIDES; PYRIDINES; RECEPTORS, DOPAMINE D2; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037328210     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00996-4     Document Type: Article

References (25)

1. The suicide rate for schizophrenia patients is difficult to estimate, but several studies indicate a range of 9-24% of people having the disease will die by committing suicide: Conwell Y., Cholette J., Duberstein P.R. Medscape Mental Health. 1998;3 Black D.W., Winokur G. Psychobiology of Suicidal Behaviour. 1986;Academy of Sciences, New York. p 106 Caldwell C.B., Gottesman I.I. Schizophr. Bull. 16:1990;571.
2. The suicide rate for schizophrenia patients is difficult to estimate, but several studies indicate a range of 9-24% of people having the disease will die by committing suicide: Conwell Y., Cholette J., Duberstein P.R. Medscape Mental Health. 1998;3 Black D.W., Winokur G. Psychobiology of Suicidal Behaviour. 1986;Academy of Sciences, New York. p 106 Caldwell C.B., Gottesman I.I. Schizophr. Bull. 16:1990;571.
3. The suicide rate for schizophrenia patients is difficult to estimate, but several studies indicate a range of 9-24% of people having the disease will die by committing suicide: Conwell Y., Cholette J., Duberstein P.R. Medscape Mental Health. 1998;3 Black D.W., Winokur G. Psychobiology of Suicidal Behaviour. 1986;Academy of Sciences, New York. p 106 Caldwell C.B., Gottesman I.I. Schizophr. Bull. 16:1990;571.
4. Gray J.A. Schizophrenia Bull. 24:1998;249.
5. King D.J. Eur. Neuropschychopharmacol. 8:1998;33 Galletly C.A., Clark C.R., McFarlane A.C., Weber D.L. Psychiatry Res. 72:1997;161.
6. King D.J. Eur. Neuropschychopharmacol. 8:1998;33 Galletly C.A., Clark C.R., McFarlane A.C., Weber D.L. Psychiatry Res. 72:1997;161.
7. Feenstra R.W., de Moes J., Hofma J.J., Kling H., Kuipers W., Long S.K., Tulp M., Th M., van der Heyden J.A.M., Kruse C.K. Bioorg. Med. Chem. Lett. 11:2001;2345.
8. Feenstra, R. W. et al. Document in preparation.
9. Tulp, M. Th. M.; van Vliet, B. J.; Tipker, J.; van Hes, R.; Visser, G.; Kruse, C. G.; van der Heyden, J. A. M.; WO00/23441, Chem. Abstr., 2000, 132, 293673. van Hes, R.; van der Heyden, J. A. M.; Kruse, C. G.; Long, S.; WO00/69424; Chem. Abstr. 2000, 134, 534.
10. Tulp, M. Th. M.; van Vliet, B. J.; Tipker, J.; van Hes, R.; Visser, G.; Kruse, C. G.; van der Heyden, J. A. M.; WO00/23441, Chem. Abstr., 2000, 132, 293673. van Hes, R.; van der Heyden, J. A. M.; Kruse, C. G.; Long, S.; WO00/69424; Chem. Abstr. 2000, 134, 534.
11. Tulp, M. Th. M.; van Vliet, B. J.; Tipker, J.; van Hes, R.; Visser, G.; Kruse, C. G.; van der Heyden, J. A. M.; WO00/23441, Chem. Abstr., 2000, 132, 293673. van Hes, R.; van der Heyden, J. A. M.; Kruse, C. G.; Long, S.; WO00/69424; Chem. Abstr. 2000, 134, 534.
12. Tulp, M. Th. M.; van Vliet, B. J.; Tipker, J.; van Hes, R.; Visser, G.; Kruse, C. G.; van der Heyden, J. A. M.; WO00/23441, Chem. Abstr., 2000, 132, 293673. van Hes, R.; van der Heyden, J. A. M.; Kruse, C. G.; Long, S.; WO00/69424; Chem. Abstr. 2000, 134, 534.
13. Goff D.C., Midha K.K., Sarid-Segal O., Hubbard J.W., Amico E. Psychopharmacology (Berl). 117:1995;417 Silver H., Barash I., Aharon N., Kaplan A., Poyurovsky M. Int. Clin. Psychopharmacol. 15:2000;257.
14. Goff D.C., Midha K.K., Sarid-Segal O., Hubbard J.W., Amico E. Psychopharmacology (Berl). 117:1995;417 Silver H., Barash I., Aharon N., Kaplan A., Poyurovsky M. Int. Clin. Psychopharmacol. 15:2000;257.
15. 2 receptor antagonism with SRI activity; Bristol-Myers Squibb Company; Mattson, R. J.; Yevich, J. P.; Yuan, J.; Eison, A. S.; DenHart, D.; WO 01/43740; Chem. Abstr. 2000, 135, 46175.
16. 2 receptor antagonism with SRI activity; Bristol-Myers Squibb Company; Mattson, R. J.; Yevich, J. P.; Yuan, J.; Eison, A. S.; DenHart, D.; WO 01/43740; Chem. Abstr. 2000, 135, 46175.
17. Gueremy C., Audiau F., Champseix A. J. Med. Chem. 23:1980;1306.
18. Perregaard J., Andersen K., Hyttel J., Sanchez C. J. Med. Chem. 35:1992;4813 Guillaume J., Dumont C., Laurent J., Nedelec L. Eur. J. Med. Chem. 22:1987;33.
19. Perregaard J., Andersen K., Hyttel J., Sanchez C. J. Med. Chem. 35:1992;4813 Guillaume J., Dumont C., Laurent J., Nedelec L. Eur. J. Med. Chem. 22:1987;33.
20. 2-N-Pht); 3.20-3.55 (bs, 2H) 2.75-2.8 (bs, 2H); 2.50-2.60 (m, 4H); 1.52-1.72 (m, 4H).
21. Costall B., Naylor R.J., Nohria V. Eur. J. Pharmacol. 1:1978;39.
22. Jacobs B.L. Life Sci. 19:1976;777.
23. Van der Heyden J.A.M., Bradford D. Behav. Brain Res. 31:1988;61.
24. Tuinstra T., Herremans A.H.J., van der Heyden J.A.M., McCreary A.C., Hesselink M.B., Kruse C.G., Long S.K. Eur. Neuropsychopharmacol. 11:2001;S251 Hesselink M.B., van Vliet B., Kruse C.G., Long S.K. Eur. Neuropsychopharmacol. 11:2001;S252.
25. Tuinstra T., Herremans A.H.J., van der Heyden J.A.M., McCreary A.C., Hesselink M.B., Kruse C.G., Long S.K. Eur. Neuropsychopharmacol. 11:2001;S251 Hesselink M.B., van Vliet B., Kruse C.G., Long S.K. Eur. Neuropsychopharmacol. 11:2001;S252.